Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Institutional review boards, which are charged with overseeing research, must classify the riskiness of proposed research according to a federal regulation known as the Common Rule (45 CFR 46, Subpart A) and by regulations governing the US Food and Drug Administration codified in 21 CFR 50. If an institutional review board determines that a clinical trial constitutes “minimal risk,” there are important practical implications: the institutional review board may then allow a waiver or alteration of the informed consent process; the study may be carried out in certain vulnerable populations; or the study may be reviewed by institutional review boards using an expedited process. However, it is unclear how institutional review boards should assess the risk levels of pragmatic clinical trials. Such trials typically compare existing, widely used medical therapies or interventions in the setting of routine clinical practice. Some of the therapies may be considered risky of themselves but the study comparing them may or may not add to that pre-existing level of risk. In this article, we examine the common interpretations of research regulations regarding minimal-risk classifications and suggest that they are marked by a high degree of variability and confusion, which in turn may ultimately harm patients by delaying or hindering potentially beneficial research. We advocate for a clear differentiation between the risks associated with a given therapy and the incremental risk incurred during research evaluating those therapies as a basic principle for evaluating the risk of a pragmatic clinical trial. We then examine two pragmatic clinical trials and consider how various factors including clinical equipoise, practice variation, research methods such as cluster randomization, and patients’ perspectives may contribute to current and evolving concepts of minimal-risk determinations, and how this understanding in turn affects the design and conduct of pragmatic clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Experimental evidence of massive-scale emotional contagion through social networks
Kramer, A. D. I., Guillory, J. E., & Hancock, J. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320040111 · Cited by 3,687
Equipoise and the Ethics of Clinical Research
Freedman, B. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707163170304 · Cited by 2,339
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
Exploring the ethical and regulatory issues in pragmatic clinical trials
Califf, R. M., & Sugarman, J. (2015) · Clinical Trials · doi:10.1177/1740774515598334 · Cited by 191
Systematic review to determine whether participation in a trial influences outcome
Vist, G. E., Hagen, K. B., Devereaux, P. J., Bryant, D., Kristoffersen, D. T., & Oxman, A. D. (2005) · BMJ · doi:10.1136/bmj.330.7501.1175 · Cited by 104
Cited by
Exploring the ethical and regulatory issues in pragmatic clinical trials
Califf, R. M., & Sugarman, J. (2015) · Clinical Trials · doi:10.1177/1740774515598334 · Cited by 191
Fishman, E., Barron, J., Dinh, J., Jones, W. S., Marshall, A., Merkh, R., Robertson, H., & Haynes, K. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.11.001 · Cited by 19
Federico, C. A., Heagerty, P. J., Lantos, J., O'Rourke, P., Rahimzadeh, V., Sugarman, J., Weinfurt, K., Wendler, D., Wilfond, B. S., & Magnus, D. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106703 · Cited by 11
Metadata
- Authors
- Lantos, J. D., Wendler, D., Septimus, E., Wahba, S., Madigan, R., & Bliss, G.
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2015-09-15
- Volume
- 12
- Issue
- 5
- Pages
- 485-493
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W2244754135
- Cited by
- 56
- References
- 5
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.